APAyusha Poudel

Ayusha Poudel

*This is an algorithmically generated author record based on publicly available information.

Ayusha Poudel has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Asbestos-Related Diseases and Its Impact on Health: An Updated Review Article

    by Wasey Ali Yadullahi Mir, Ayusha Poudel, Anurag Adhikari, Dhan Bahadur Shrestha, Yubraj Sedhai, Peter LaCamera, Andrew Moraco


  • Sa1572 IMPACT OF PROTEIN ENERGY MALNUTRITION ON INFECTIOUS OUTCOMES OF HOSPITALIZATIONS FOR CIRRHOSIS: A NATIONWIDE RETROSPECTIVE COHORT STUDY

    by Sania Saleem, Bashar M. Attar, Chun-Wei Pan, Muhammad Ali Khaqan, Muhammad Bilal Ibrahim, Ayusha Poudel

  • Open Access

    An Adult Female Presenting With "Scrofula-Tubercular Lymphadenitis" a Rare Encounter: A Case Report

    by Anuradha Sakhuja, Dhan B. Shrestha, Ayusha Poudel, Wasey Ali Yadullahi Mir, Tilak Joshi

    Cervical lymphadenitis is the most common extra-pulmonary manifestation of tuberculosis (TB). Usually, presenting with a neck mass with minimal systemic symptoms is a diagnostic challenge for physicians. Diagnosis is made by combining clinical features, microscopic and radiological imaging, and fine-needle aspiration biopsy. A biopsy is the simplest and most cost-effective means of diagnosis. We are reporting a case of a female presenting with a neck mass without systemic symptoms who were found to have lymph node TB along with active lung disease. She was treated with a nine-month course of the direct observation treatment regimen.

  • Open Access

    Superior Sagittal Sinus Thrombosis in a Young, Immunocompetent HIV Patient: A Rare Case

    by Wasey Ali Yadullahi Mir, Dhan B. Shrestha, Ayusha Poudel, Vijay K. Reddy, Thomas Sullivan

    Cerebral venous thrombosis is a rare form of stroke that can present with various clinical features. In addition, it can present with nonspecific neurological features, and initial computed tomography (CT) cannot rule it out even if negative. Human immunodeficiency virus (HIV) infection is a hypercoagulable state; however, it is not much discussed. Here, we present a case of a 24-year-old immunocompetent female who presented with acute meningeal symptoms. She was managed as a case of an opportunistic central nervous system infection at initial presentation, which did not resolve her symptoms completely. Later, however, cerebral thrombosis was diagnosed, and she improved symptomatically on anticoagulants.

  • Open Access

    Use of Tocilizumab May Avoid the Need of Invasive Ventilation

    by Anurag Adhikari, Ayusha Poudel, Oshna Pandey, Barun B. Aryal, Bibek Dhungana

    Coronavirus disease 2019 (COVID-19) is an illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Increased pro-inflammatory cytokines including interleukin 6 (IL-6) are associated with severe forms of illnesses. The severe cases of COVID-19 require a high amount of oxygen supplementation and might even require endotracheal intubation with ventilator support. A blockade of inflammatory cascade with the use of tocilizumab has been shown to decrease the need for intubation and ventilator requirement.

  • Top Cited Papers
    Open Access

    D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19

    by Ayusha Poudel, Yashasa Poudel, Anurag Adhikari, Barun Babu Aryal, Debika Dangol, Tamanna Bajracharya, Anil Maharjan, Rakshya Gautam

    Introduction: Coronavirus Disease 2019 is a primarily respiratory illness that can cause thrombotic disorders. Elevation of D-dimer is a potential biomarker for poor prognosis in COVID-19, though optimal cutoff value for D-dimer to predict mortality has not yet been established. This study aims to assess the accuracy of admission D-dimer in the prognosis of COVID-19 and to establish the optimal cutoff D-dimer value to predict hospital mortality. Methods: Clinical and laboratory parameters and outcomes of confirmed COVID-19 cases admitted to four hospitals in Kathmandu were retrospectively analyzed. Admitted COVID-19 cases with recorded D-dimer and definitive outcomes were included consecutively. D-dimer was measured using immunofluorescence assay and reported in Fibrinogen Equivalent Unit (μg/ml). The receiver operating characteristic curve was used to determine the accuracy of D-dimer in predicting mortality, and to calculate the optimal cutoff value, based on which patients were divided into two groups and predictive value of D-dimer for mortality was measured. Results: 182 patients were included in the study out of which 34(18.7%) died during the hospital stay. The mean admission D-dimer among surviving patients was 1.067 μg/ml (±1.705 μg/ml), whereas that among patients who died was 3.208 μg/ml (±2.613 μg/ml). ROC curve for D-dimer and mortality gave an area under the curve of 0.807 (95% CI 0.728–0.886, p<0.001). Optimal cutoff value for D-dimer was 1.5 μg/ml (sensitivity 70.6%, specificity 78.4%). On Cox proportional hazards regression analysis, the unadjusted hazard ratio for high D-dimer was 6.809 (95% CI 3.249–14.268, p<0.001), and 5.862 (95% CI 2.751–12.489, p<0.001) when adjusted for age. Conclusion: D-dimer value on admission is an accurate biomarker for predicting mortality in patients with COVID-19. 1.5 μg/ml is the optimal cutoff value of admission D-dimer for predicting mortality in COVID-19 patients.


  • Open Access

    Recurrent Pneumothorax in an Adult Male With Bilateral COVID-19 Pneumonia

    by Ayusha Poudel, Anurag Adhikari, Barun B. Aryal, Yashasa Poudel, Ishu Shrestha

    Pneumothorax is defined as the condition in which air is collected between the visceral and parietal pleura. Pneumothorax as a complication of coronavirus disease 2019 (COVID-19) infection has been reported in relatively few cases and recurrent pneumothorax is even rarer. We present a case of a 50-year-old critically ill patient who required mechanical ventilation for 55 days and developed recurrent bilateral pneumothorax. The patient initially presented with shortness of breath and cough. He was found to be COVID-19 positive on the polymerase chain reaction (PCR) test. Subsequently, his oxygen demand increased, and he ultimately needed mechanical ventilation. He developed four episodes of pneumothorax. The patient was managed in all four episodes with intercostal tube insertion. To prevent subsequent episodes, pleurodesis was performed after the fourth episode of pneumothorax.


  • Open Access

    Successful Treatment of Respiratory Syncytial Virus Infection in an Immunocompromised Patient With Ribavirin

    by Wasey Ali Yadullahi Mir, Dhan B. Shrestha, Wajahath Rana, Shravani Reddy Yelma Reddy, Ayusha Paudel, Larissa Verda

    Respiratory syncytial virus (RSV) is a frequent cause of respiratory tract infections in children. Still, it can also cause seasonal outbreaks affecting persons of all ages, especially those with comorbidities or immunocompromised states. Ribavirin is one of the two approved therapies for the treatment of RSV respiratory tract infections. Unfortunately, its aerosolized formulation has been approved only in children, and the oral formulation is not frequently used to treat the infection. However, ribavirin has demonstrated morbidity and mortality benefit in immunocompromised patients. A 70-year-old female had started chemotherapy for a diagnosis of B-cell acute lymphoblastic leukemia (B-ALL). She developed an upper respiratory tract infection (URTI) along with positive RSV status. We started her on oral ribavirin therapy, which had to be stopped after five days of treatment due to an acute hemolytic reaction. She was re-initiated on oral ribavirin after cessation of medication for seven days and showed improvement. Therefore, ribavirin can be used in immunocompromised patients with RSV infection under proper supervision.


  • Open Access

    Type 2 Diabetes Mellitus in Nepal from 2000 to 2020: A systematic review and meta-analysis

    by Dhan Bahadur Shrestha, Pravash Budhathoki, Yub Raj Sedhai, Achyut Marahatta, Samit Lamichhane, Sarbin Nepal, Anurag Adhikari, Ayusha Poudel, Samata Nepal, Alok Atreya

    Aims: To evaluate the prevalence and risk factors of type 2 diabetes mellitus (T2DM) from 2000-2020 in various parts of Nepal. Methods: PubMed, Embase, Scopus, and Google Scholar were searched using the appropriate keywords. All Nepalese studies mentioning the prevalence of T2DM and/or details such as risk factors were included. Studies were screened using Covidence. Two reviewers independently selected studies based on the inclusion criteria. Meta-analysis was conducted using Comprehensive Meta-Analysis Software v.3. Results: Total 15 studies met the inclusion criteria. The prevalence of T2DM, pre-diabetes, and impaired glucose tolerance in Nepal in the last two decades was 10% (CI, 7.1%- 13.9%), 19.4% (CI, 11.2%- 31.3%), and 11.0% (CI, 4.3%- 25.4%) respectively. The prevalence of T2DM in the year 2010-15 was 7.75% (CI, 3.67-15.61), and it increased to 11.24% between 2015-2020 (CI, 7.89-15.77). There were 2.19 times higher odds of having T2DM if the body mass index was ≥24.9 kg/m 2 . Analysis showed normal waist circumference, normal blood pressure, and no history of T2DM in a family has 64.1%, 62.1%, and 67.3% lower odds of having T2DM, respectively. Conclusion: The prevalence of T2DM, pre-diabetes, and impaired glucose tolerance in Nepal was estimated to be 10%, 19.4%, and 11% respectively.